Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/07/23
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline UpdateBusiness Wire • 08/07/23
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer StudyBusiness Wire • 06/03/23
Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness Wire • 05/30/23
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug ClassInvestors Business Daily • 05/26/23
Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences' Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of CancerBusiness Wire • 05/17/23
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in InflammationBusiness Wire • 05/15/23
Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline UpdateBusiness Wire • 05/09/23
Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to DeclineZacks Investment Research • 05/01/23
Arcus Biosciences to Participate in the Barclays Global Healthcare ConferenceBusiness Wire • 03/02/23
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline UpdateBusiness Wire • 02/28/23
Down -45.21% in 4 Weeks, Here's Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a TurnaroundZacks Investment Research • 01/12/23
Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor expectationsProactive Investors • 12/20/22
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drugMarket Watch • 12/20/22
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer StudyBusiness Wire • 12/19/22
Wall Street Analysts Believe Arcus Biosciences, Inc. (RCUS) Could Rally 45%: Here's is How to TradeZacks Investment Research • 11/29/22
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That SurgesInvestors Business Daily • 11/28/22
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung CancerBusiness Wire • 11/28/22
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung CancerBusiness Wire • 11/28/22